By Chelsea Naso ( November 20, 2015, 7:35 PM EST) -- The Internal Revenue Service's latest move to crack down on so-called inversion transactions will limit some flexibility and curb certain post-closing benefits, but the upcoming rule changes are not enough to put a stop to tax-motivated deal structures like the one Pfizer is said to be mulling, experts say....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.